<DOC>
	<DOC>NCT02408796</DOC>
	<brief_summary>This is a 1-month, prospective, multicenter, open-label study in pediatric subjects with either unilateral or bilateral acute otitis media with tympanostomy tubes (AOMT). Eligible subjects will receive a single dose of 6 mg OTO-201 to the affected ear(s). The study is designed to characterize safety, procedural factors and clinical effect of OTO-201 administered in subjects with AOMT.</brief_summary>
	<brief_title>Open-Label Study of OTO-201 for Treatment of AOMT</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject is a male or female aged 6 months to 17 years, inclusive Subject has a clinical diagnosis of acute otitis media with tympanostomy tubes (AOMT) Subject's caregiver is willing to comply with the protocol an attend all study visits Exclusion Criteria includes, but is not limited to: Subject has a history of sensorineural hearing loss Subject has tympanic membrane perforation other than the surgical tympanostomy tube perforation Subject has a history of known immunodeficiency disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Acute otitis media with tympanostomy tubes</keyword>
</DOC>